Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer Presented ByDr Jeroen van Dorp, Netherlands Cancer Institute, the Netherlands TrialPhase 1, NABUCCO ConferenceESMO 2021 19 November, 2021 09:26